

STATE OF KANSAS
KANSAS PHARMACY BOARD


**NOTICE OF PUBLIC HEARING ON
ADMINISTRATIVE REGULATION**

A public hearing will be conducted at 9:00 a.m., on the 23rd day of April, 2015, at the Board of Healing Arts Board Room, 800 SW Jackson, Lower Level, Topeka, Kansas, to consider the proposed adoption of K.A.R. 68-20-31 by the Kansas Pharmacy Board.

This 60-day notice of the public hearing shall constitute a public comment period for the purpose of receiving written public comments on the proposed adoption of K.A.R. 68-20-31. All parties may submit written comments prior to the hearing to the Executive Secretary of the Kansas Pharmacy Board, Debra Billingsley, pharmacy@pharmacy.ks.gov or 800 SW Jackson, Suite 1414, Topeka, Kansas 66612. All interested parties will be given a reasonable opportunity to present their views orally on the regulations during the hearing. In order to give all parties an opportunity to present their views, it may be necessary to request each participant to limit any oral presentation to five minutes.

Any individual with a disability may request accommodation in order to participate in the public hearing and may request the regulation and economic impact statement in an accessible format. Requests for accommodation to participate in the hearing should be made at least five working days in advance of the hearing by contacting the Kansas Pharmacy Board, 800 SW Jackson, Suite 1414, Topeka, Kansas 66612, (785) 296-4056. Handicapped parking is located in the parking lot at the Board of Healing Arts Board Room, 800 SW Jackson, Lower Level, Topeka, Kansas.

K.A.R. 68-20-31 is a new permanent regulation. The following is a summary of the new regulation.




K.A.R. 68-20-31. 2,5-dimethoxy-4-methyl-n-(2-methoxybenzyl)phenethylamine included in schedule I. 2,5-dimethoxy-4-methyl-n-(2-methoxybenzyl)phenethylamine, including its salts, isomers, and salts of isomers, shall be classified as a schedule I controlled substance.

The Board does not anticipate any economic impact to the Kansas Board of Pharmacy. The Board does not anticipate a financial impact on other governmental agencies, licensees and registrants, or private businesses or individuals other than the costs associated with prosecuting and defending criminal charges for illegally possessing this substance.

Copies of the regulation and the economic impact statement may be obtained from the Kansas Pharmacy Board, 800 SW Jackson, Suite 1414, Topeka, Kansas 66612, (785) 296-4056, or by accessing the Board's website at <http://pharmacy.ks.gov/home>.


Debra Billingsley
Executive Secretary



Proposed


68-20-31. 2,5-dimethoxy-4-methyl-n-(2-methoxybenzyl)phenethylamine included in schedule I. 2,5-dimethoxy-4-methyl-n-(2-methoxybenzyl)phenethylamine, including its salts, isomers, and salts of isomers, shall be classified as a schedule I controlled substance.

(Authorized by and implementing K.S.A. 2014 Supp. 65-4102; effective, T-_____, _____; effective P-_____.)



ATTORNEY GENERAL

NOV 24 2014

APPROVED BY 

APPROVED

NOV 18 2014

DEPT. OF ADMINISTRATION

**KANSAS BOARD OF PHARMACY
ECONOMIC IMPACT STATEMENT
K.A.R. 68-20-31**

I. Summary of Proposed Regulation, Including Its Purpose.

K.A.R. 68-20-31 is a new permanent regulation that classifies 2,5-dimethoxy-4-methyl-n-(2-methoxybenzyl)phenethylamine, including its salts, isomers, and salts of isomers, as a schedule I controlled substance.

II. Reason or Reasons the Proposed Regulation Is Required, Including Whether or Not the Regulation Is Mandated by Federal Law.

This permanent regulation is necessary to supersede the temporary regulation and protect the public health, safety, and welfare. The Board of Pharmacy was requested by the Johnson County Assistant District Attorney, pursuant to K.S.A. 21-5715 to adopt a temporary regulation scheduling of 2,5-dimethoxy-4-methyl-n-(2-methoxybenzyl)phenethylamine, including its salts, isomers, and salts of isomers, as a controlled substance analog. This regulation is not mandated by federal law.

III. Anticipated Economic Impact upon the Kansas Board of Pharmacy.

The Board does not anticipate any economic impact.

IV. Anticipated Financial Impact upon Other Governmental Agencies and upon Private Business or Individuals.

The Board does not anticipate a financial impact on other governmental agencies or on private businesses or individuals, other than the costs associated with prosecuting and defending criminal charges for illegally possessing this substance.

